748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
oleh: Daniel Olson, Manish Sharma, Erminia Massarelli, Jonathan Thompson, Rachel E Sanborn, Ralph J Hauke, Anthony W Tolcher, Elizabeth Davis, Conor Steuer, Muhammad Furqan, John Hamm, Doug Laux, David Berz, Wade T Iams, Vasily Andrianov, Brianne O’Neill, Yaiza Diaz De Durana
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2023-11-01 |
Deskripsi
No description available for this item.